Betrixaban: Safely Reducing Venous Thromboembolic Events with Extended Prophylaxis

Published:September 07, 2018DOI:


      Although venous thromboembolism prophylaxis of acute medically ill patients is commonly employed, a percentage of high-risk patients still have venous thromboembolic events within 30 days of discharge. Research over the last several years has attempted to identify characteristics of these high-risk patients to facilitate provision of extended prophylaxis and venous thromboembolic event reduction; however, extended prophylaxis has been associated with a significant increase in the risk for major bleeding until recently. Betrixaban, a new oral direct Xa inhibitor with once-daily dosing and limited renal elimination, significantly reduces the risk of venous thromboembolism without increasing the risk for major bleeding. Consequently, betrixaban is the only anticoagulant approved by the Food and Drug Administration for preventing venous thromboembolism with extended prophylaxis in acute medically ill patients.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Chan NC
        • Hirsh J
        • Ginsberg JS
        • Eikelboom JW
        Betrixaban (PRT054021): pharmacology, dose selection and clinical studies.
        Future Cardiol. 2014; 10: 43-52
        • Bouthier J
        The venous thrombotic risk in nonsurgical patients.
        Drugs. 1996; 52: 16-29
        • Goldhaber SZ
        • Tapson VF
        • DVT FREE Steering Committee
        A prospective registry of 5451 patients with ultrasound-confirmed deep vein thrombosis.
        Am J Cardiol. 2004; 93: 259-262
        • Dobesh PP
        Economic burden of venous thromboembolism in hospitalized patients.
        Pharmacotherapy. 2009; 29: 943-953
        • Kahn SR
        • Lim W
        • Dunn AS
        • et al.
        Prevention of VTE in nonsurgical patients antithrombotic therapy and prevention of thrombosis.
        Chest. 2012; 141: e195S-e226S
      1. Performance Measurement Initiatives. The Joint Commission website. Available at: Accessed June 22, 2018.

        • Enders JM
        • Burke JM
        • Dobesh PP
        Prevention of venous thromboembolism in acute medical illness.
        Pharmacotherapy. 2002; 22: 1564-1578
        • Heit JA
        • Crusan DJ
        • Ashrani AA
        • Petterson TM
        • Bailey KR
        Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US.
        Blood. 2017; 130: 109-114
        • Korjian S
        • Daaboul Y
        • Halaby R
        • et al.
        Extended-duration thromboprophylaxis among acute medically ill patients: an unmet need.
        J Cardiovasc Pharmacol Therap. 2016; 21: 227-232
        • Amin A
        • Varker H
        • Princic N
        • Lin J
        • Thompson S
        • Johnston S
        Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients.
        J Hosp Med. 2012; 7: 231-238
        • Spencer FA
        • Lessard D
        • Emery C
        • Reed G
        • Goldberg RJ
        Venous thromboembolism in the outpatient setting.
        Arch Intern Med. 2007; 167: 1471-1475
        • Spyropoulos AC
        • Anderson FA
        • Fitzgerald G
        • et al.
        Predictive and associative models to identify hospitalized medical patients at risk for VTE.
        Chest. 2011; 140: 706-714
        • Hull RD
        • Schellong SM
        • Tapson VF
        • et al.
        Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
        Ann Intern Med. 2010; 153: 8-18
        • Goldhaber SZ
        • Leizorovicz A
        • Kakkar AK
        • et al.
        Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
        N Engl J Med. 2011; 365: 2167-2177
        • Cohen AT
        • Spiro TE
        • Büller HR
        • et al.
        Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
        N Engl J Med. 2013; 368: 513-523
        • Cave B
        • Hough A
        • Dobesh PP
        Extended venous thromboembolism prophylaxis in medically ill patients.
        Pharmacotherapy. 2018; 38: 597-609
      2. Portola Pharmaceuticals. Bevyxxa dosing and administration. Available at: Accessed August 15, 2018.

        • Hutchaleelaha A
        • Ye SongY
        • Lorenz T
        • Gretler D
        • Lambing J
        Metabolism and disposition of betrixaban and its lack of interaction with major CYP enzymes.
        Blood. 2012; 120: 2266
        • Palladino M
        • Merli G
        • Thomson L
        Evaluation of the oral direct factor Xa inhibitor—betrixaban.
        Expert Opin Investig Drugs. 2013; 22: 1465-1472
        • Cohen AT
        • Harrington RA
        • Goldhaber SZ
        • et al.
        Extended thromboprophylaxis with betrixaban in acutely ill medical patients.
        N Engl J Med. 2016; 375: 534-544
        • Gibson M
        • Halaby R
        • Korjian S
        • et al.
        The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (venous thromboembolism) Prevention with Extended-Duration Betrixaban (APEX) trial.
        Am Heart J. 2017; 185: 93-100
        • Gibson CM
        • Korjian S
        • Halaby R
        • et al.
        Extended duration betrixaban reduces the risk of venous thromboembolism versus standard duration enoxaparin in the post-parenteral period among hospitalized medically ill patients.
        J Am Coll Cardiol. 2017; 69: 1859
        • Gibson CM
        • Korjian S
        • Chi G
        • et al.
        Comparison of fatal or irreversible events with extended-duration betrixaban versus standard dose enoxaparin in acutely ill medical patients: an APEX trial substudy.
        J Am Heart Assoc. 2017; 6e006015
        • Chi G
        • Yee MK
        • Amin AN
        • et al.
        Extended-duration betrixaban reduces the risk of rehospitalization associated with venous thromboembolism among acutely ill hospitalized medical patients: findings from the APEX trial (Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban trial).
        Circulation. 2017; 137: 91-94
        • Gibson CM
        • Chi G
        • Halaby R
        • et al.
        Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients: an APEX trial substudy (Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban).
        Circulation. 2016; 135: 648-655
        • Gibson CM
        • Nafee T
        • Goldhaber SZ
        • et al.
        Full-dose betrixaban reduces venous thromboembolism-related mortality: an APEX trial substudy.
        Circulation. 2017; 136: A20393
        • Cohen AT
        • Huang W
        • Harrington RA
        • et al.
        Prevalence of major medical illnesses associated with venous thromboembolism risk in US hospitals.
        Res Pract Thromb Haemost. 2017; 1: 177-178